Phase 3 Results of Bavarian Nordic’s Smallpox Vaccine Published in The New England Journal of Medicine
COPENHAGEN, Denmark, November 14, 2019 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that results from the pivotal Phase 3 efficacy trial of its smallpox vaccine, MVA-BN®, have been peer-reviewed and published in The New England Journal of …